Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 129 posts found.

Pfizer Xalkori

US rivals Pfizer and Merck team up for lung cancer

August 27, 2014
Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab

The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …

News
Roche image

Roche lung cancer drug sees first approval

July 4, 2014
Sales and Marketing ALK+, Cancer, NSCLC, Pfizer, Roche, Xalkori, alectinib, alk, zykadia

Roche has seen the first approval for its new lung cancer drug alectinib in Japan as it looks to compete …

News
boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

News
AZ image

AstraZeneca lung cancer data reveals promise

May 15, 2014
Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer

AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …

News
astrazeneca_plaque

AstraZeneca begins lung cancer trial

May 9, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer

AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …

News
GSK image

Lung cancer vaccine dropped

April 2, 2014
Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit

GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …

News
Xalkori image

Pfizer’s Xalkori impresses in new setting

March 26, 2014
Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer

Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …

News
MSD image

Endocyte lung cancer drug shows promise

March 24, 2014
Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide

Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …

News
GSK image

GSK cancer vaccine fails again

March 20, 2014
Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma

GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials.  The …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News
Sarah Edwards image

Breaking into the oncology market

March 10, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology

In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …

Feature
roche_logo_shadow

Roche lung cancer drug fails

March 3, 2014
Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin

An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …

News
Alimta image

NICE rejects Alimta

February 28, 2014
Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed

Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …

News
lilly_outside_plaque_1

Lilly drug improves lung cancer survival

February 21, 2014
Research and Development, Sales and Marketing NSCLC, lilly, necitumumab, ramucirumab

News
Roche image

Roche: NICE guidance ‘perverse’

February 4, 2014
Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva

Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023